

Drugs in Oral Fluid Scheme Issue No: 8 Issue Date: May 2016

## Instructions for Handling Test Materials and Recording Results

## Samples

The 3 enclosed samples are prepared from oral fluid collected from volunteers and patients which has been heated at 60°C for 1½ hours. Nevertheless, it is recommended that laboratory personnel treat the samples with the care and attention normally exercised in handling clinical specimens. Each sample is neat oral fluid without addition of diluent buffer, however the samples obtained from known drug users may contain a small amount of the buffers encountered in oral fluid kits and occasionally a small amount (0.25%) of the non-ionic surfactant Tritox X-100 may be used to stabilise the sample. All samples contain gentamicin 0.1 g/L and penicillin 0.1 g/L as preservatives.

Samples are of 1.7ml volume. Check the code number printed on the label carefully to distinguish between the three samples. Samples should be stored at 4°C for up to 2 days or frozen if analysis is to be delayed.

Screen the samples for drugs of abuse and please follow your normal protocol when analysing the samples. The samples may be analysed directly or can be diluted first with appropriate stabilisation buffer to mimic your routine samples. Please express any quantitative findings in terms of the drug concentration present in the undiluted sample.

#### Please Note: Cut-offs for users of commercial kits

Participants who use commercial kits that operate to threshold concentrations different from those tabulated should report their results to those specified by the manufacture of the kit. A problem only arises in the uncommon case where the kit threshold is above the scheme threshold. In a sample containing a drug at a concentration between the two thresholds, the laboratory will receive an unsatisfactory result. When a drug is present at a concentration below the scheme threshold, no assessment is applied.

#### Threshold after hydrolysis

In the case of drug groups, where a sample hydrolysis step may be employed, the tabulated threshold should be taken to apply to the total sample content; free + conjugated.

#### Submission of results

This scheme allows participants to report results for screening groups and individual analytes, the options available are: detected, not detected, not tested and referred. Quantitative results may also be reported.

#### **Reporting units**

For the submission of results mass and molar units are available to participants. However, for the majority of analytes the report will be produced in mass units.

#### All results should be submitted using PORTAL.

Please go to https://www.lgcpt.com/portal

Login using your Lab ID, username and password.

PORTAL user advice has been supplied in the sample package and in the sample despatch email. Further guides can be downloaded from the help section.

Please note that this scheme utilises a screening profile. The screening profile will need to be configured on PORTAL prior to reporting results. Please refer to the quick guide sent in the sample despatch email.

Please do no hesitate to contact our support team using the details below or your local LGC representative if any difficulties are encountered. Tel: +44 (0)161 762 2500 Email: ptcustomerservices@lgcgroup.com



Drugs in Oral Fluid Scheme Issue No: 8 Issue Date: May 2016

# Instructions for Handling Test Materials and Recording Results

## **Reporting thresholds**

The scheme operates to the threshold values recommended by the European Workplace Drug Testing Society in their guidelines published as <u>http://www.ewdts.org/ewdts-guidelines.html</u>. The thresholds are tabulated below. Analytes marked with an asterisk (\*) have values suggested by the scheme.

Screening tests	μg/L	Single analytes (total)	µg/L
Amfetamines screen	40	Amfetamine	15
		Methyl-amfetamine MDMA / MDA / MDEA Other members of the amphetamine	15 15
Barbiturates* screen	60	group Specific barbiturate*	10
Benzodiazepines screen	10	Specific benzodiazepines: 7-aminoflunitrazepam 7-amino-clonazepam 7-amino-nitrazepam Alprazolam Bromazepam Clonazepam Desmethyldiazepam (Nordiazepam) Diazepam Flunitrazepam Lorazepam Lorretazepam Midazolam Nitrazepam Oxazepam Phenazepam Temazepam	3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 10
Cannabinoid screen (THC)	10	Delta-9-THC	2
Cocaine and metabolites screen	30	Benzoylecgonine Cocaine Cocaethylene	8 8 -
Methadone screen EDDP screen	50	Methadone EDDP	20
Propoxyphene and metabolites screen	40	Propoxyphene or metabolite	5
Opiates screen	40	Morphine Codeine Norcodeine 6-Acetylcodeine Dihydrocodeine	15 15 2 2 15
6-Monoacetylmorphine screen	4	6-Monoacetylmorphine	2
Buprenorphine and metabolites screen	5	Buprenorphine or metabolites	1
Phencyclidine* screen	10	Phencyclidine*	10
LSD and metabolites* screen	1	LSD or metabolites*	1

LGC Standards Proficiency Testing

1 Chamberhall Business Park, Chamberhall Green, Bury, Lancashire, BL9 0AP Telephone: +44 (0) 161 762 2500, Fax: +44 (0) 161 762 2501

Email: dof@lgcgroup.com Website: www.lgcstandards.com